AxoGen (NASDAQ:AXGN) Announces Quarterly Earnings Results

AxoGen (NASDAQ:AXGN) announced its earnings results on Tuesday. The medical equipment provider reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.03), Zacks reports. AxoGen had a negative net margin of 7.91% and a negative return on equity of 14.91%. AxoGen updated its FY 2025 guidance to EPS.

AxoGen Stock Up 0.1 %

Shares of NASDAQ AXGN opened at $18.01 on Tuesday. The stock has a market cap of $792.62 million, a PE ratio of -56.28 and a beta of 1.00. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67. AxoGen has a 12-month low of $5.55 and a 12-month high of $19.19. The company has a 50-day moving average of $17.36 and a 200 day moving average of $14.87.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group boosted their price target on AxoGen from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.